Signatur Biosciences
YC S22London, GB · Founded 2022 · 5 employees · 2 known investors
Signatur Biosciences develops molecular diagnostic solutions using qPCR technology for in vitro diagnostics, targeting clinical and laboratory markets. The company aims to deliver advanced diagnostics on widely available instrumentation to expand access to cutting-edge healthcare globally.
BiotechDigital HealthHealthtechMedical DevicesHealthcareDiagnosticsUnited KingdomEuropePartly Remote
Founders & leadership· Y Combinator alumni (S22)
Signatur Biosciences was founded in 2022 by John Goertz, Celestin de Wergifosse, and Celestin de Wergifiosse.
JG
John Goertzin𝕏Co-founder · Chief Scientific Officer2022–2025John Goertz is co-founder and chief scientific officer at Signatur Biosciences, where he applies machine learning to PCR-based diagnostics. He completed postdoctoral research at Imperial College London's Stevens Group as an NIH F32 fellow, and holds a PhD in bioengineering from the University of Maryland, College Park and a BSc in physics and cell & molecular biology from Seattle University.
CD
Celestin de Wergifossein𝕏Co-founder and CEOHe studied bio-engineering at Imperial College London and has founded multiple ventures including Young Change Maker and Sauna en Bois, the latter of which he sold.
CD
Celestin de WergifiosseCEO
Board
PD
Prof Dame Molly Stevensin𝕏Scientific Advisory Board Chair, Co-inventorNon-Executive Director at Oxford Science Enterprises
Investors · 2
Competitors · 1
by search overlap
Companies competing with Signatur Biosciences for the same Google search keywords, organic and paid, via search-intersection analysis.
Companies House · registry record
View on Companies House ↗- Registered name
- SIGNATUR BIOSCIENCES LTD
- Company number
- 14027651
- Status
- Active
- Company type
- Private limited company
- Incorporated
- 5 Apr 2022
- Registered office
- 30 Upper High Street, Thame, Oxfordshire, OX9 3EZ
- Nature of business (SIC)
- 71122 — Engineering related scientific and technical consulting activities
- Accounts
- last made up to 30 Apr 2025 · next due 31 Jan 2027
- Confirmation statement
- last made up to 4 Apr 2026 · next due 18 Apr 2027
Current officers · 1
- Celestin De Wergifosse — director, appointed 5 Apr 2022
Source: Companies House public register · retrieved 24 Jul 2026. Contains public sector information licensed under the Open Government Licence v3.0.
In the news
Frequently asked questions
- What does Signatur Biosciences do?
- Signatur Biosciences develops molecular diagnostic solutions using qPCR technology for in vitro diagnostics, targeting clinical and laboratory markets. The company aims to deliver advanced diagnostics on widely available instrumentation to expand access to cutting-edge healthcare globally.
- Who founded Signatur Biosciences?
- Signatur Biosciences was founded by John Goertz, Celestin de Wergifosse, Celestin de Wergifiosse in 2022.
- Who are Signatur Biosciences's investors?
- Signatur Biosciences's investors include Myelin VC, Y Combinator.
- Where is Signatur Biosciences headquartered?
- Signatur Biosciences is headquartered in London, GB.